Trista Morrison

Pain Therapeutics Hits Goals In Remoxy Phase III Trial

Dec. 7, 2007

Adolor Inks $265M Deal With Pfizer For Opioid

Dec. 6, 2007

Adolor Corp.'s beleaguered shares got a 20 percent boost on Wednesday after the company announced a $265 million deal with Pfizer Inc. for the delta opioid agonists ADL5859 and ADL5747. (BioWorld Today)

Adolor Inks $265M Deal With Pfizer For Opioid

Dec. 6, 2007

By Trista Morrison

Adolor Corp.'s beleaguered shares got a 20 percent boost on Wednesday after the company announced a $265 million deal with Pfizer Inc. for the delta opioid agonists ADL5859 and ADL5747. (BioWorld Today)

Maxygen Licenses Antigens To Sanofi Group For $24.5M

Dec. 5, 2007

By Trista Morrison

Maxygen Licenses Antigens To Sanofi Group For $24.5M

Dec. 5, 2007

By Trista Morrison

Targacept's TC-2696 Fails Trial; Other NNR Programs Advance

Dec. 4, 2007

By Trista Morrison

Targacept's TC-2696 Fails Trial; Other NNR Programs Advance

Dec. 4, 2007

By Trista Morrison

Fate Tempts VCs With Viable Stem Cell Business Model

Dec. 3, 2007

By Trista Morrison

Amid a flurry of stem cell news, Fate Therapeutics raised $12 million in a Series A financing to pursue in vivo and ex vivo modulation of adult stem cells. (BioWorld Today)

Fate Tempts VCs With Viable Stem Cell Business Model

Dec. 3, 2007

By Trista Morrison

Amid a flurry of stem cell news, Fate Therapeutics raised $12 million in a Series A financing to pursue in vivo and ex vivo modulation of adult stem cells. (BioWorld Today)